Gemcitabine Hydrochloride

Home > API & Intermediate > Antineoplastic Agents > Gemcitabine Hydrochloride Manufacturers > Gemcitabine Hydrochloride

CAS NO.： 122111-03-9

FOB Price： NEGOTIABLE Get Latest Price

Specification： GMP/ DMF/ CEP/DCGI/MFDS

Documentation： Get COA after inquiry

Lead Time： In Stock

Max Capacity： 10MT/Year

Pallets Packing	20'FCL		40'FCL
Pallets Packing	With	Without	With	Without
25KG/Fibre Drum	--	20 MT	--	--

Product Detail

Properties

Gemcitabine hydrochloride

Name in English: gemcitabinehydrochloride

CAS number: 122111-03-9

Molecular formula:C9H12ClF2N3O4

Structural formula:

MW: 299.66

EINECS number: 601-823-3

Purpose: it is indicated for the treatment of inoperable advanced or metastatic pancreatic cancer and for the treatment of locally progressive or metastatic non-small cell lung cancer, intermediate - and advanced non-small cell lung cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

Properties

Gemcitabine hydrochloride is a synthetic new type of two fluoronucleoside antitumor drug developed by Eli Lilly. It was approved in 1995 in South Africa, Sweden, Holland, Australia and other countries. In 1996, the US Food and Drug Administration approved the first line treatment for non-small cell lung cancer and pancreatic cancer. Gemcitabine hydrochloride, a nucleoside homologue, is a cell cycle specific antitumor drug. It mainly kills cells in S phase (DNA synthesis) and blocks the transition of cell proliferation from G1 to S phase. Gemcitabine is suitable for the treatment of advanced or metastatic pancreatic cancer and locally advanced or metastatic non-small cell lung cancer, advanced and non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.

CAS No.

122111-03-9

Formula

C9H12ClF2N3O4

Molecular Mass

299.65900

Exact Mass

299.04800

PSA

110.60000

Logp

0.09460